Tenderwize
Back to tender search

Medicinal products with the active substance Erythropoietin (ATC: B03XA01 - in strength up to 10,000 IU per dose unit)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2026 · 8 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Erythropoietin (ATC: B03XA01 - in der Wirkstärke bis 10.000 IE je Dosiereinheit)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

30 / 100

Risk factors

Buyer may terminate contracts early if exclusive contracts are awarded later; no compensation mentioned.

No estimated value; revenue potential is uncertain.

Submission deadline in 8 days

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for erythropoietin medications (ATC B03XA01, strength up to 10,000 IU per dose unit)
  • Open-house model with continuous application possibility
Show full summary

This is an open-house model for non-exclusive discount agreements under German social law (§130a SGB V) for erythropoietin medications (ATC B03XA01, strength up to 10,000 IU per dose unit). The buyer is AOK Sachsen-Anhalt. There is no competitive award; any eligible pharmaceutical company can join. The contract duration is up to 24 months (01.11.2024 to 31.10.2026). No estimated value is provided. The notice is published for transparency only and explicitly states it is not a public procurement.

Risks

Buyer may terminate contracts early if exclusive contracts are awarded later; no compensation mentioned.

No estimated value; revenue potential is uncertain.

Submission deadline in 8 days

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies
  • Must comply with standard contract conditions

Administrative

  • Must request and submit participation documents completely and signed

Requirements may be incomplete.

Award Criteria

Lot 1

Open-house: no competitive award; all eligible companies are accepted.

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Medicinal products with the active substance Erythropoietin (ATC: B03XA01 - in strength up to 10,000 IU per dose unit)

Non-exclusive discount agreements for erythropoietin medications under an open-house model. Any eligible pharmaceutical company can conclude a contract at any time. Contract duration up to 24 months, ending 31.10.2026 regardless of start date.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Award Criteria

Open-house: no competitive award; all eligible companies are accepted.

Deadline

Deadline Aug 31, 2026

Procurement Details

Publication date
19 Sep 2024
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
566953-2024

Documents (1)

Similar tenders